Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 4/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10346512 | 0.92 | PDE4A (0.54) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL14541204 | 0.91 | ADORA2A (0.48) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL8482322 | 0.89 | PDE4A (0.49) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL19601304 | 0.88 | PDE4A (0.58) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL10346307 | 0.88 | LMNA (0.61) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL14507751 | 0.88 | PDE4A (0.61) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL5427270 | 0.87 | PDE4A (0.70) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL14507749 | 0.87 | PDE4A (0.60) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL7452667 | 0.86 | LMNA (0.48) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL7358934 | 0.86 | PDE4A (0.69) | PDE4ALMNACYP1A2NFKB1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 710 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214443-A1 | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-07-15 | — | — | US | claimed |
| US-20210093636-A1 | Arylamide compounds and compositions and uses thereof | INNOVATION PHARMACEUTICALS INC. | 2021-04-01 | — | — | US | claimed |
| US-10954300-B2 | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-03-23 | — | — | US | claimed |
| US-20190314370-A1 | Arylamide compounds and compositions and uses thereof | POLYMEDIX, INC. | 2019-10-17 | — | — | US | claimed |
| US-20180319886-A1 | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-08 | — | — | US | claimed |
| EP-2614827-B1 | Means and methods for counteracting muscle disorders | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2017-06-28 | — | — | EP | claimed |
| US-9668972-B2 | Nonsteroidal immunomodulating kit and composition and uses thereof | FOAMIX PHARMACEUTICALS LTD. (IL) | 2017-06-06 | — | — | US | claimed |
| US-20160228435-A1 | Arylamide compounds and compositions and uses thereof | INNOVATION PHARMACEUTICALS INC. | 2016-08-11 | — | — | US | claimed |
| US-9192623-B2 | Arylamide compounds and compositions and uses thereof | CELLCEUTIX CORPORATION (US) | 2015-11-24 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-0544391-A1 | Compositions for topical treatment of psoriasis and atopic dermatitis | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-06-02 | — | — | EP | claimed |
| EP-0305743-B1 | PHARMACEUTICAL MIXTURE PREPARATION, ITS MANUFACTURE AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-04 | — | — | EP | claimed |
| US-5118500-A | Side effect reduction when administering a xanthine derivative | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | claimed |
| EP-0462506-A1 | Pharmaceutical preparations of mixtures comprising cefotaxim and derivatives of xanthine and their use | Schrinner, Elmar J., Dr. (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0414175-A2 | Use of xanthine derivatives to reduce nephrotoxicity | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-02-27 | — | — | EP | claimed |
| EP-0268585-B1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| US-4833146-A | BRAINS, BLOOD DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-23 | — | — | US | claimed |
| EP-0305743-A2 | Pharmaceutical mixture preparation, its manufacture and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-08 | — | — | EP | claimed |
| EP-0268585-A1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF. | HOECHST AG (DE) | 1988-06-01 | — | — | EP | claimed |
| WO-1987000523-A2 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314370-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PDE4A 2077/4885LMNA 1014/4885CYP1A2 2421/4885 |
| US-20160228435-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PDE4A 2077/4885LMNA 1014/4885CYP1A2 2421/4885 |
| US-20210093636-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PDE4A 2077/4885LMNA 1014/4885CYP1A2 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.